A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2201 and co-administration of each component in fasting condition in healthy male volunteers.

Inclusion Criteria:Age 19~55 years in healthy male volunteers19 kg/m^2 ≤ BMI < 28 kg/m^2, weight ≥55kg90 mmHg ≤ SBP <140 mmHg, 50 mmHg ≤ DBP <90 mmHgAgrees that the person, spouse, or partner uses appropriate medically recognized contraception and does not provide sperm from the date of administration of the first investigational drug to 7 days after the administration of the last investigational drug.Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trialExclusion Criteria:Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular systemSubjects who judged ineligible by the investigator